4080 super game benchmarks THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen

Dan Walters: How three Trump policy decrees could affect California agricultureNone

ITV's The Martin Lewis Money Show hit with complaints as fans say same thing about guestAfter Trump's Project 2025 denials, he is tapping its authors and influencers for key roles

Weekly Horoscope Aquarius, November 24 to 30, 2024 predicts a fresh start!Pinstripes Reports Fiscal 2025 Second Quarter Results

In a significant development amidst the ongoing Middle East crisis, US President Joe Biden on Tuesday announced that Israel and Lebanon have agreed to a ceasefire, bringing an end to the ongoing conflict between Israel and Hezbollah. Speaking from the White House’s Rose Garden, Biden outlined the terms of the agreement, which aims for a permanent cessation of hostilities and a pathway toward stability in the region. "Today, I have good news to report from the Middle East. I have spoken to the Prime Ministers of Lebanon and Israel. And I am pleased to announce: They have accepted the United States’ proposal to end the devastating conflict between Israel and Hezbollah," the outgoing US President said. The ceasefire will take effect at 02:00 GMT (4:00 local time) on Wednesday. Over the following 60 days, the Lebanese army and state security forces will deploy across southern Lebanon, asserting control over their territory. Concurrently, Israeli forces will gradually withdraw, allowing displaced civilians on both sides to return to their communities and rebuild their lives. “This is designed to be a permanent cessation of hostilities,” Biden said, emphasizing the US’s commitment to ensuring the deal is implemented effectively. He extended gratitude to French President Emmanuel Macron for his collaborative efforts in brokering the agreement. Biden stressed that the arrangement includes guarantees to prevent Hezbollah and other militant groups from threatening Israel’s security. He also reaffirmed if Hezbollah or any other party breaks the ceasefire deal, then Israel retains the right to self-defence “consistent with international law”. The US, with backing from France and other allies, will provide necessary assistance to both Israel and Lebanon to ensure the ceasefire holds. In his remarks, Biden also addressed the ongoing conflict in Gaza, highlighting the urgent need for peace. Biden stressed that the agreement “heralds a new start for Lebanon”. “Just as the Lebanese people deserve a future of security and prosperity, so do the people of Gaza,” Biden said. "People of Gaza have been through hell, their world is absolutely shattered," he added. Biden further noted that Hamas has refused for months to negotiate a good faith ceasefire and hostage deal, and said Hamas “has a choice to make”. "Hamas’s “only way out” is to release the remaining hostages and bring an end to the fighting, which would allow humanitarian relief into Gaza," the US President stated. "Over the coming days, the United States will make another push for Turkey, Egypt, Qatar, Israel and others to achieve a ceasefire in Gaza," he added. Looking ahead, Biden reiterated his vision for a peaceful Middle East, including the establishment of a Palestinian state and normalization of relations between Israel and Saudi Arabia. Biden said today's announcement brings the world closer to realising his vision for a future of the Middle East in which Israelis and Palestinians can enjoy “equal measures of security, prosperity and dignity”, and where Palestinians “have a state of their own”. The US remains prepared to conclude a set of “historic” deals with Saudi Arabia to include a security pact and economic assurances, Biden added. He further highlighted that the US remains committed to creating a “credible pathway” for establishing a Palestinian state and the full normalisation of relations between Saudi Arabia and Israel. Achieving this will require some “hard choices”, Biden noted. "Israel must be bold in turning tactical gains against Iran and its proxies into a coherent strategy that secures Israel’s long term safety, and advances a broader peace and prosperity in the region," the US President said. Biden concluded by commending the leadership in Lebanon and Israel for their decision to embrace peace. “It reminds us that peace is possible,” he said, calling the ceasefire a critical step toward long-term stability and prosperity in the region. As the world watches, the coming days will test the durability of this agreement and its potential to reshape the dynamics in the Middle East.

White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaignNORTH CHARLESTON, S.C. (AP) — Nick Anderson's 14 points helped Furman defeat Charleston Southern 67-46 on Saturday. Anderson shot 6 for 9, including 2 for 4 from beyond the arc for the Paladins (6-0). Pjay Smith Jr. scored 13 points while going 6 of 12 (1 for 5 from 3-point range) and added five assists. Garrett Hien finished 5 of 9 from the field to finish with 10 points, while adding six rebounds. The Paladins picked up their sixth straight win. The Buccaneers (1-6) were led in scoring by Daylen Berry, who finished with 16 points. Charleston Southern also got nine points and four assists from RJ Johnson. Jaylon Gibson finished with eight points, eight rebounds and three blocks. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .YouTube star-turned-boxer Jake Paul has expressed his desire to face former heavyweight champion Anthony Joshua in the ring. Fresh from his stunning victory over boxing icon Mike Tyson, Paul’s aspirations signal a bold move into the heavyweight division. Paul’s promotional partner, Nakisa Bidarian, revealed the ambitious plan during an interview with Sky Sports. “Jake’s feedback to me was, ‘I want to do that fight. Not now. But I want to do that.’ To be a world champion at cruiserweight, he wants to do that,” Bidarian said. While Paul’s career has already disrupted traditional boxing norms, a bout with Joshua or other heavyweight contenders like Daniel Dubois would test new boundaries. Bidarian noted that the motivation behind these fights isn’t financial, as Paul has been a millionaire since age 18, but rather to “test the limits of what’s possible” and deliver moments that captivate the world. “Jake weighed in at 227lbs for the Tyson fight but walks around at 215lbs,” Bidarian added. Related News Continent’s best clash at African Knockout Championship ‘Joshua should wait for Fury fight’ Ajagba poised for world title shot “For the right environment and framework, he’s willing to go beyond expectations. It’s about doing things that make people say, ‘Wow, that really happened.’” Paul’s intentions come amid speculation about Joshua’s future in boxing. Former unified light-welterweight world champion Amir Khan recently advised Joshua to focus on a highly anticipated bout with Tyson Fury before retiring. “Joshua should wait for the big fight against Tyson Fury,” Khan told *New Zealand Daily*. “AJ has done phenomenal in boxing... but why not finish on a big high by taking the Fury fight and then call it a day?” Joshua, who has earned over $200m in his career, is currently recovering from injuries sustained during his knockout loss to IBF heavyweight champion Daniel Dubois in September. Promoter Eddie Hearn has confirmed that Joshua is unlikely to return to the ring before May 2024. Meanwhile, Fury is preparing for a rematch with unified champion Oleksandr Usyk after losing his WBC heavyweight title in a split decision earlier this year. Should Fury fail to reclaim the title, there is speculation that a Joshua-Fury bout could be staged under Saudi Arabia’s Riyadh Season banner, promising significant financial backing.

Gordon tours UW plant growth lab, touts innovationAT THE QUARTER MARK: Ottawa Senators remain confidentFrom launching a war on disinformation to being a trailblazer for equal cancer treatment options and giving new freedom to those living with a disability, Australia has said "thanks" to this year's most remarkable mature citizens. or signup to continue reading Standing tall among state winners of the in November, were their Senior counterparts including celebrity scientist , former AFL health physician Dr Peter Brukner and women's cancer specialist Associate Professor Penelope Blomfield. The latter spoke with ACM's following her Tasmanian award and admitted she wasn't very good at retirement. The 65-year-old has dedicated her life to improving the quality and longevity of life for women affected by gynaecological cancers and has remained a beacon of the advancement of medical research. "I made sure that whether a woman was in the public system or in the private system, they got prompt access and best care irrespective of what system they were in," she said. Read more about . Inspired by the efforts of a disadvantaged friend, Peter and Marilyn Ralston and vision impaired and founded Canberra's first chapter of the Achilles Running Club. Together, they have helped pair volunteer guides with people with disability so they can enjoy the health benefits of running and walking. Read more about the . Michael Foley, 84, has dedicated most of his life to giving back by donating his time to better other peoples , community and helping seniors in his community. He was named NT's Senior Australian of the Year, as a "proud example of the value seniors bring to our society",said Mark Fraser, National Australia Day Council CEO. Read more about . Charles Jackson OAM has used his multiple languages, skills and educational opportunities to bridge cultural divides and improve the lives of others and has been honoured with the SA Senior Australian of the Year award. Among the roles he's held are a services coordinator, cultural awareness teacher, marriage celebrant and NDIS officer. He was the first in Australia to become a JP in 1978. He is a knowledge holder for Flinders Ranges Nation and is working towards getting Wilpena Pound on the World Heritage List. Mr Jackson's new business, Urndu, helps the Aboriginal community through offering culturally appropriate training and giving support and resources for people with disabilities or age-related impairments. "The way that we live, the way that we walk, the way that we talk and, and how we communicate... that's where respect comes from," he said. Popular scientist, author and media personality Dr Karl Kruszelnicki has been named NSW Senior Australian of the Year for his ongoing efforts to educate the public about science. "At the moment I have five full time jobs and I'm about to start a sixth," he said. He works for the University of Sydney and the ABC, is a highly sought after corporate and public speaker, has a new TV show in development and is currently working on another book. As for that soon to be added sixth job, it could be an absolute game changer. Trying to counteract the spread of disinformation has long been a key goal for Dr Karl. It was a baby's death from whooping cough due to vaccine disinformation that convinced him to walk away from a job in paediatric medicine to pursue a career in the media as a science educator. Fed up with constantly seeing disinformation shared on his social media feeds, he is putting together a team to develop an AI chatbot in a bid to change minds. Dr Karl will work with AI experts and psychologists to develop the technology. Read more about . Out of a factory workshop in Perth, more than 61,000 custom-built wheelchairs have been gifted to children in 81 developing countries and remote Australian First Nation communities thanks to Christian Brother Thomas Oliver (Olly) Pickett. The 84-year-old co-founded along with the Rotary Club of Scarborough in 1996 and is this year's WA Senior Australian of the Year. "The wheelchairs mean the little kids can get off the ground, go to the village school to get an education and they can grow up and get a job and then contribute to their communities," said Olly. Read more about . Once on the verge of "obese", Peter Brukner wants to use his newfound accolade - VIC Senior Australian of the Year - to tell everyone to eat better. As a sports medicine physician for AFL clubs and team manager of the Sydney Olympics, somehow the kilos slowly crept on due to following (like many Australians, he said) the wrong nutrition advice. "We've been told for 30 or 40 years now to stop eating fat and I think that was probably the wrong emphasis," Dr Brukner said. "Ever since we've started doing that, we've just got fatter and sicker... Now, people are increasingly understanding that it wasn't necessarily fat that was a problem, [it] was more sugar and processed foods." Read more about . has spent most of her adulthood working to improve the lives and experiences of others especially families in crisis and those who face homelessness. Last year, at the age of 90 the long-time social worker proved learning is for life when she received her PhD after completing her thesis on the generational impacts of homelessness. This year at 91, she has been named the Australian Senior of the Year for Queensland. Dr Herbert stopped working in social work at 81 - a time when most people are well into retirement, so she could concentrate on writing her thesis. At her PhD graduation from the University of Queensland' s she was an inspiration for all the other graduates. Read more about The state and territory award recipients will join together for the national awards to be presented in Canberra on the eve of Australia Day, January 25, 2025. ACM, publisher of this masthead, is official media partner of the . DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement Advertisement

After Trump's Project 2025 denials, he is tapping its authors and influencers for key roles"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen